Sentences with phrase «gynecologic oncology»
"Gynecologic oncology" is a medical specialty that focuses on the diagnosis and treatment of cancers that occur in women's reproductive organs, such as the ovaries, uterus, cervix, vagina, and vulva. Full definition
«Now that we know exactly how changes in EMSY spur cancer cell growth, we can start to design therapies to specifically target that activity and hopefully stop it,» says senior author Douglas Levine, MD, director of the Division of Gynecologic Oncology at NYU Langone and its Perlmutter Cancer Center.
sciencedaily.com
In the Phase II clinical trial, Dr. Miller and colleagues in the National Cancer Institute - supported Gynecologic Oncology Group found that in patients who had not received prior chemotherapy, the combination cocktail had a 31 percent response rate for up to 7 months, and an overall survival of 12 months.
Our approach is to study more than one or two serial recurrences of the disease, adding information about the response to therapy and natural progress of ovarian cancer,» adds J. Brian Szender, MD, MS, senior author and a fellow in Gynecologic Oncology at RPCI.
Programs: Anatomic Pathology Services, Center for Head and Neck Cancer, Gynecologic Oncology Program
«We've known for years that how well a patient does is directly related to the amount of tumor that the surgeon removes and the amount that's left behind,» says Michael Birrer, who began working with Belcher when he was head of medical gynecologic oncology at Massachusetts General Hospital.
«Estimating from various studies that looked at increasing BMI and endometrial cancer risk, a woman with a Body Mass Index (BMI) of 40 would have approximately eight times greater risk of endometrial cancer than someone with a BMI of 25,» said first author Kristy Ward, MD, the senior gynecologic oncology fellow in the Department of Reproductive Medicine at UC San Diego School of Medicine.
«We found that pemetrexed combined with cisplatin is less toxic, well tolerated, and should be developed for further treatment of cervical cancer,» said gynecologic oncology specialist Dr. David Miller, Professor of Obstetrics and Gynecology and a member of the Harold C. Simmons Cancer Center.
Using radioactive dye and blue dye, gynecologic oncology surgeons are able to identify and remove just the sentinel nodes, which is the first place cancer will go.
In 2013, the Society of Gynecologic Oncology recommended the removal of the fallopian tubes during routine hysterectomies, a procedure called opportunistic salpingectomy, in order to reduce the risk of ovarian cancer.
The Medical College of Georgia at Augusta University is establishing the state of Georgia's first gynecologic oncology fellowship program to train physicians who diagnose and treat the cancers that...
Brian M. Slomovitz, M.D., co-leader of the Gynecologic Cancers Site Disease Group at Sylvester Comprehensive Cancer Center, received the 2018 Presidential Abstract Award from the Society for Gynecologic Oncology on March 24 during the group's Annual Meeting on Women's Cancer in New Orleans.
The Department of Obstetrics and Gynecology is comprised of the Program in Women's Oncology that includes Gynecologic Oncology and Breast Health, Maternal - Fetal Medicine, Midwifery, Reproductive Endocrinology and Infertility, specialists in General Obstetrics and Gynecology including Ambulatory Care and Emergency Obstetrics and Gynecology, Clinical Research in Women's Health, Medical Education, and Urogynecology and Reconstructive Pelvic Surgery.
She is director of the Kelly Gynecologic Oncology Service at Johns Hopkins University School of Medicine in Baltimore.
It presents the latest diagnostic procedures, leading - edge research, and expert commentary in maternal - fetal medicine, reproductive endocrinology and infertility, and gynecologic oncology as well as general obstetrics and gynecology.
TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.
Our findings suggest that abstinence from regular physical activity is associated with increased odds of cervical cancer,» says J. Brian Szender, MD, MPH, lead author of the study and a fellow in the Department of Gynecologic Oncology at Roswell Park.
Results of the study appeared online in the journal Gynecologic Oncology.
Programs: Breast Cancer Program, Gastrointestinal Cancer Program, Gynecologic Oncology Program, Mariann and Robert MacDonald Cancer Risk Evaluation Center
Were on our way,» says Linda Duska, MD, associate professor of gynecologic oncology at the University of Virginia.
«Clinicians will need to make decisions based upon the specific subsets of patients with advanced ovarian cancer, including the stage of the cancer,» added Dr. Ursula Matulonis, director of medical gynecologic oncology at Dana - Farber Cancer Institute and an associate professor of medicine at Harvard Medical School in Boston.
«Given that pemetrexed combined with cisplatin may be less toxic than and as active as cisplatin plus paclitaxel and that it can be combined with bevacizumab, investigating the comparison of cisplatin - pemetrexed plus bevacizumab with cisplatin - paclitaxel plus bevacizumab would be the next appropriate step,» said Dr. Miller, who holds the Amy and Vernon E. Faulconer Distinguished Chair in Medical Science and the Dallas Foundation Chair in Gynecologic Oncology.
About Youtuber For more than 30 years, OHC medical, radiation and gynecologic oncology specialists have been treating nearly every form of cancer and complex blood disorders.
Also published today in Gynecologic Oncology is the end - of - trial data of the Roche Diagnostics ATHENA HPV trial that enrolled more than 47,000 women in a longitudinal, three - year study of Roche's HPV test.
They do this «by activating the portion of the immune response which initiates and helps control tissue repair,» the researchers note in the June 2017 issue of Gynecologic Oncology.
Published in the April issue of Gynecologic Oncology, the official publication of the Society of Gynecologic Oncology, the findings indicate obesity may be a modifiable risk factor for endometrial cancer, and bariatric surgery a viable option for eligible patients.
The combination of drugs appeared less toxic than standard chemotherapy, were relatively inexpensive and should be clinically evaluated, said Dwayne G. Stupack, PhD, the study's senior author and associate professor in the dDivision of Gynecologic Oncology at Moores Cancer Center.
«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.
Society of Gynecologic Oncology.
Materials provided by Society of Gynecologic Oncology.
Gynecologic cancer cells that have a BRCA mutation appear to be sensitive to veliparib, which targets an enzyme called PARP (poly ADP - ribose polymerase), according to a Phase II study being presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Tampa, Fla., March 22 - 25.
The trial was run by Professor Bradley J. Monk MD who directs the Division of Gynecologic Oncology at the University of Arizona Cancer Center at St. Joseph's in Phoenix and sponsored by Amgen.
She will conduct the trial in collaboration with Steven Waggoner, MD, division chief of gynecologic oncology at University Hospitals Seidman Cancer Center and professor of obstetrics and gynecology at Case Western Reserve University School of Medicine.
«This ratio proved to be a robust marker for prognosis,» said MD Anderson co-author Anil Sood, professor of gynecologic oncology and reproductive medicine and co-director of the Center for RNA Interference and Non-Coding RNA.
Stewart Massad is chief of the gynecologic oncology division at the Southern Illinois University School of Medicine in Springfield.
«Though surgery isn't right for every patient, we suspect that some women do not receive beneficial surgical treatment because they have poor access to specialty care,» said David I. Shalowitz, MD, a fellow in Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania.
«This is the first national study to identify specific regions of the United States where residents may be at an increased risk for poor clinical outcomes — including misdiagnoses and late detection — as a result of limited access to specialized gynecologic cancer care,» says David Shalowitz, MD, a fellow in the division of Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on the study.
The study is published this month in the journal Gynecologic Oncology.
This study, conducted by the Gynecologic Oncology Group, a cooperative group funded by the National Cancer Institute, was the second to test bevacizumab under these conditions (first chemotherapy for platinum - sensitive recurrence), a use for which bevacizumab is not currently approved by the Food and Drug Administration.
The preliminary findings were reported here at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer.
«Early stage disease is curable,» adds co-author Bernadette Cracchiolo, director of gynecologic oncology at the school, «but late stage and recurrent disease have limited treatment options.
First author Alpa Nick, M.D., assistant professor of Gynecologic Oncology, and colleagues also note that computed tomography (CT) imaging and analysis of bloodborne proteins associated with ovarian cancer, such as CA - 125, have so far failed to predict which patients would benefit from surgery first.
«Our algorithm allows us to be much smarter about whom we operate on up front, providing a more individualized approach to surgery that's led to better results for our patients,» said Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine and senior author of the paper.
This study adds to the discussion about the role of this immunosurveillance in the risk of developing the common cancers among those with compromised immune systems,» adds first author Paul Mayor, MD, Fellow in the Department of Gynecologic Oncology at RPCI.
Based on these results, two phase 3 trials are being planned for platinum - sensitive and platinum - resistant ovarian cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).
This is a key conclusion of new research from Roswell Park Cancer Institute (RPCI), published online ahead of print in the journal Gynecologic Oncology, that contributes new information about the dynamics of recurrent ovarian cancer.